The Share Purchase Agreement (SPA) secures an equity stake in FacialDx and secures ownership in its intellectual property by way of the shareholding. The SPA also enables Synbio to convert future clinical trial expenditures into additional equity in FacialDx at today’s valuation, unlocking substantial upside potential as FaciaDx also scales commercially. A Joint Trial Committee will be established to oversee the design, conduct, and reporting of all clinical studies, maximizing the likelihood...